Lyell takes on J&J and Gilead
The players are vying in the CD19 x CD20 Car-T arena.
Galapagos split stutters
The group’s point-of-care Car-T push looks to have stalled.
Crispr’s Car-T crunch time
The group could soon provide clarity on CTX112’s regulatory path.
Make or break time for Caribou
The company’s matching strategy for CB-010 will soon be put to the test.
AstraZeneca doubles down on GPC3
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
More bad vibes kill off Merck’s TIGIT and Lag3
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
Regeneron keeps up its co-stimulatory crusade
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
